Integra LifeSciences Holdings (IART)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 2.49% | 11.34% | 10.37% | 65.53% | 65.20% |
| Operating profit margin | 7.50% | 15.86% | 12.86% | 11.66% | 6.42% |
| Pretax margin | 5.45% | 14.20% | 14.00% | 7.20% | 4.11% |
| Net profit margin | 4.56% | 11.98% | 11.02% | 10.31% | 3.43% |
Integra Lifesciences Holdings Corp's profitability ratios have shown some fluctuations over the past five years.
1. Gross profit margin: The gross profit margin has declined from 62.79% in 2019 to 57.39% in 2023. This indicates a decrease in the percentage of revenue that remains after accounting for the cost of goods sold.
2. Operating profit margin: The operating profit margin has also experienced variability, dropping from 10.46% in 2019 to 7.23% in 2023. This suggests a decrease in the proportion of revenue that converts to operating profit after deducting operating expenses.
3. Pretax margin: The pretax margin has fluctuated over the years, with a notable increase in 2021 and 2022 compared to previous years. However, there was a decrease in 2023 to 5.26%. This metric reflects the percentage of revenue remaining after accounting for all expenses but before taxes.
4. Net profit margin: The net profit margin has shown variability, increasing from 3.31% in 2019 to 11.59% in 2022 before declining to 4.39% in 2023. This ratio indicates the proportion of revenue that converts to net income after accounting for all expenses, including taxes.
Overall, the profitability ratios of Integra Lifesciences Holdings Corp have shown some fluctuations over the years, with varying trends in gross profit margin, operating profit margin, pretax margin, and net profit margin. Further analysis would be needed to understand the factors driving these changes and assess the company's overall profitability performance.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 2.95% | 6.14% | 5.21% | 4.19% | 2.84% |
| Return on assets (ROA) | 1.79% | 4.64% | 4.47% | 3.70% | 1.52% |
| Return on total capital | 4.44% | 8.49% | 8.62% | 5.65% | 4.36% |
| Return on equity (ROE) | 4.27% | 10.01% | 10.04% | 8.84% | 3.54% |
Integra Lifesciences Holdings Corp has displayed varying levels of profitability over the past five years based on the provided ratios.
The Operating Return on Assets (Operating ROA) has shown a downward trend from 6.14% in 2022 to 2.95% in 2023, indicating a decrease in the company's ability to generate operating income from its total assets.
Return on Assets (ROA) also demonstrates a fluctuating pattern, with a notable increase from 3.70% in 2020 to 4.64% in 2022, followed by a decline to 1.79% in 2023. This ratio highlights the firm's capability to generate profits from its total assets, showing some inconsistency in performance.
Return on total capital has exhibited a similar pattern to ROA, with a peak of 7.36% in 2022 and a decline to 3.61% in 2023. This metric reflects the company's efficiency in generating returns from its total invested capital.
Return on Equity (ROE) has shown a fluctuating trend with the highest value of 10.01% in 2022 and the lowest at 3.54% in 2019. This ratio signifies the firm's ability to generate returns for its shareholders from the equity invested in the business.
In conclusion, Integra Lifesciences Holdings Corp's profitability ratios indicate some variability in performance over the years, with fluctuations in operating efficiency and profitability levels. Further investigation may be warranted to understand the factors driving these changes in profitability.